Anna W Coleman
Overview
Explore the profile of Anna W Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang H, Gupta A, Morrisroe S, Bao C, Schwantes-An T, Gupta G, et al.
Circulation
. 2024 May;
150(4):302-316.
PMID: 38695173
Background: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin...
2.
Simpson C, Griffiths M, Yang J, Nies M, Vaidya D, Brandal S, et al.
ERJ Open Res
. 2022 Jun;
8(2).
PMID: 35769420
https://bit.ly/3shXrNR.
3.
Yang J, Ambade A, Nies M, Griffiths M, Damico R, Vaidya D, et al.
Pulm Circ
. 2022 May;
12(1):e12007.
PMID: 35506100
Hepatoma-derived growth factor (HDGF) was previously shown to be associated with increased mortality in a small study of idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH). In this study,...
4.
Zhu N, Pauciulo M, Welch C, Lutz K, Coleman A, Gonzaga-Jauregui C, et al.
Genome Med
. 2022 Feb;
14(1):12.
PMID: 35130931
No abstract available.
5.
Simpson C, Griffiths M, Yang J, Nies M, Vaidya R, Brandal S, et al.
ERJ Open Res
. 2021 Oct;
7(4.
PMID: 34651041
Currently available noninvasive markers for assessing disease severity and mortality risk in pulmonary arterial hypertension (PAH) are unrelated to fundamental disease biology. Endostatin, an angiostatic peptide known to inhibit pulmonary...
6.
Zhu N, Swietlik E, Welch C, Pauciulo M, Hagen J, Zhou X, et al.
Genome Med
. 2021 Jun;
13(1):106.
PMID: 34158098
No abstract available.
7.
Zhu N, Swietlik E, Welch C, Pauciulo M, Hagen J, Zhou X, et al.
Genome Med
. 2021 May;
13(1):80.
PMID: 33971972
Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy characterized by pathogenic remodeling of pulmonary arterioles leading to increased pulmonary pressures, right ventricular hypertrophy, and heart failure. PAH can be...
8.
Swietlik E, Greene D, Zhu N, Megy K, Cogliano M, Rajaram S, et al.
Circ Genom Precis Med
. 2020 Dec;
PMID: 33320693
- Approximately 25% of patients with pulmonary arterial hypertension (PAH) have been found to harbor rare mutations in disease-causing genes. To identify missing heritability in PAH we integrated deep phenotyping...
9.
Potus F, Pauciulo M, Cook E, Zhu N, Hsieh A, Welch C, et al.
Circulation
. 2020 Mar;
141(24):1986-2000.
PMID: 32192357
Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy. Hereditary cases are associated with germline mutations in and 16 other genes; however, these mutations occur in <25% of patients with...
10.
Simpson C, Chen J, Damico R, Hassoun P, Martin L, Yang J, et al.
Eur Respir J
. 2020 Feb;
55(4).
PMID: 32029443
The pro-inflammatory cytokine interleukin (IL)-6 has been associated with outcomes in small pulmonary arterial hypertension (PAH) cohorts composed largely of patients with severe idiopathic PAH (IPAH). It is unclear whether...